UCB's Global Corporate Website

This section is intended for media and financial analysts

Search Press releases

17 Feb 2005

FDA grants priority review to levetiracetam for use in childhood epilepsy

Read More
7 Feb 2005

UCB Group preliminary full-year 2004 results

Read More
25 Jan 2005

UCB Pharma enters into agreement to collaborate on two Biotherapeutic Inflammation Programs with Millennium

Read More
19 Jan 2005

UCB Confirms Annual Zyrtec Sales In The US - Xyzal Sells More Than Zyrtec In Europe

Read More
23 Dec 2004

Xyzal®* Is The First And Only Antihistamine Licensed For Persistent Allergic Rhinitis

Read More
17 Dec 2004

UCB: research budget for 2005 up significantly after conversion to biopharmaceutics

Read More

Stay up-to-date on the latest news and information from UCB